2BBBullish & Bearish
Lineage Cell Therapeutics, Inc. (LCTX) trades on NYSEAMERICAN. It operates in the Health Care sector, Biotechnology industry. Its current 2BB score is 24 out of 100.
Lineage Cell Therapeutics is a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs. Lineage’s programs are based on its proprietary cell-based therapy platform and associated development and manufacturing capabilities.
Lineage Cell Therapeutics, Inc.’s current 2BB score is 24 out of 100, built from the signal categories below.
| Signal | Score | Reading |
|---|---|---|
| Activity | 4 | Very Low |
| Momentum | 50 | Stable |
| Financial strength | 25 | Weak |
| Quality | 80 | Very Strong |
| Risk | 50 | Moderate (provisional) |
| Founded | 1990 |
| Employees | 75 |
| 52-week range | $0.88 – $1.99 |
| Report date | EPS actual | EPS estimate | Revenue actual | Revenue estimate |
|---|---|---|---|---|
| 2027-03-03 | — | -0.0044 | — | $4.21M |
| 2026-11-12 | — | -0.0291 | — | $2.03M |